selk2
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 20, 2019 (NCT03812328)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- P-selectin glycoprotein ligand 1INHIBITOR
SELPLG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04540042 | Phase 2 | Aug 18, 2020 | Tetherex Pharmaceuticals Corporation |
| NCT03812328 | Phase 2 | Feb 20, 2019 | Tetherex Pharmaceuticals Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tetherex Pharmaceuticals Corporation | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1